Does Purdue’s Reformulated OxyContin ER Really Deter Abuse? US FDA Panel To Decide
Executive Summary
Five years after an advisory committee meeting was cancelled, panel will consider whether required postmarketing studies show Purdue’s reformulated opioid ‘meaningfully’ reduces abuse and overdose.